3Q US Biotech VC Investment Balancing Atop Industry's Peak
This article was originally published in Scrip
The $2.06bn in venture capital that private US biotechnology firms raised during the third quarter almost matched the industry's near record-breaking second quarter total, keeping 2015 VC investment on track to beat 2014 despite a downturn in public biotech valuations that began in the third quarter.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.